When patients experience sudden sensorineural hearing loss (SSNHL), the clock starts ticking. This emergency condition—characterized by rapid hearing loss of 30 decibels or more across at least three contiguous frequencies—demands intervention within days to preserve auditory function. While corticosteroids remain the standard first-line treatment, researchers continue exploring adjunctive therapies that might tip the odds toward recovery. A new retrospective study from Taiwan adds an interesting twist to this quest, examining whether blocking a cluster of nerves in the neck could enhance the well-documented benefits of hyperbaric oxygen therapy.
The research, published in August 2026 in the journal Life, represents one of the first systematic comparisons of stellate ganglion block (SGB) combined with HBOT against either therapy alone for SSNHL patients. The stellate ganglion—a star-shaped collection of sympathetic nerves located at the base of the neck—regulates blood flow to the head and neck region. By injecting local anesthetic around these nerves, clinicians aim to interrupt sympathetic overactivity and improve vascular perfusion to the delicate structures of the inner ear.
Three Arms, One Goal
The Taiwanese research team analyzed outcomes across three treatment cohorts: patients receiving HBOT alone, those undergoing stellate ganglion block alone, and a combination group receiving both interventions. This three-arm design allowed researchers to isolate the individual contributions of each modality while testing for potential synergistic effects when used together.
HBOT’s rationale in SSNHL treatment rests on well-established physiology. The increased atmospheric pressure—typically 2.0 to 2.5 ATA (atmospheres absolute)—dissolves oxygen directly into plasma, dramatically increasing oxygen availability to the cochlea. The inner ear’s stria vascularis, responsible for maintaining the ionic gradients essential for hearing, operates at the edge of vascular supply and is exquisitely sensitive to hypoxia. By flooding the system with oxygen, HBOT aims to rescue metabolically stressed hair cells and support the recovery of auditory function.
The addition of stellate ganglion block introduces a complementary mechanism. Sympathetic nervous system overactivity can cause vasoconstriction in the cochlear blood supply, potentially exacerbating ischemic insult. By temporarily blocking sympathetic outflow, SGB may dilate cochlear vessels and improve microcirculatory flow. The combination theory suggests that HBOT delivers the oxygen while SGB opens the vascular channels to distribute it—a physiological tag-team approach.
What the Data Showed
While the full study details await broader dissemination, the research team’s findings suggest that the combination approach outperformed either monotherapy. Patients receiving both HBOT and stellate ganglion block demonstrated superior hearing recovery compared to those receiving single-modality treatment. The improvement appeared consistent across multiple audiometric measures, including pure-tone average and speech discrimination scores.
The timing of intervention emerged as a critical factor, consistent with previous SSNHL literature. Patients treated within the first two weeks of symptom onset showed markedly better outcomes than those with delayed presentation—a reminder that SSNHL remains a true otologic emergency requiring immediate evaluation and treatment initiation.
Notably, the study adds to a growing body of literature exploring combination therapies for SSNHL. Previous investigations have examined HBOT paired with intratympanic steroid injection, oral corticosteroids combined with antiviral agents, and various vasodilator protocols. The stellate ganglion block approach, however, represents a relatively novel addition to this therapeutic armamentarium.
The FDA Perspective: Cleared but Contextualized
For patients and clinicians navigating treatment decisions, the regulatory status of these interventions matters. Idiopathic sudden sensorineural hearing loss (ISSNHL) holds a firm position on the FDA’s list of cleared indications for hyperbaric oxygen therapy—a status granted based on substantial evidence demonstrating benefit when treatment begins promptly after symptom onset.
The FDA clearance specifically covers HBOT as an adjunct to standard medical therapy, typically defined as systemic corticosteroids. This regulatory green light provides patients and insurers with confidence that HBOT for SSNHL rests on solid evidentiary ground, unlike many wellness applications marketed through direct-to-consumer channels.
However, stellate ganglion block occupies a different regulatory category. While widely used for various conditions including complex regional pain syndrome and post-traumatic stress disorder, SGB for hearing loss represents an off-label application. The procedure carries its own risk profile—including potential injury to surrounding structures, bleeding, and temporary Horner’s syndrome (ptosis, miosis, and anhidrosis on the affected side).
The FDA maintains a clear position on unapproved HBOT uses, and patients should understand that combination approaches like SGB plus HBOT fall outside the specifically cleared indication. This doesn’t necessarily mean the approach lacks merit—only that the evidentiary threshold for regulatory approval hasn’t been formally met.
The Safety Landscape
Both interventions in this combination carry manageable but real risks. HBOT’s safety profile includes barotrauma to ears or sinuses, oxygen toxicity seizures (rare, occurring in approximately 1 in 10,000 treatments), and the omnipresent fire risk inherent in pressurized oxygen environments. The FDA’s August 2025 safety communication to healthcare providers specifically highlighted the importance of following manufacturer instructions for HBOT devices following reports of serious injuries and deaths from chamber fires.
Stellate ganglion block introduces procedural risks including pneumothorax, vascular puncture, esophageal perforation, and intrathecal injection. These complications remain uncommon in experienced hands but underscore the importance of seeking treatment at facilities with demonstrated expertise in both interventions.
Implications for Clinical Practice
The Taiwanese study, while retrospective and thus limited by inherent selection biases and confounding variables, contributes to an evolving conversation about SSNHL treatment optimization. The combination of HBOT with SGB may offer particular benefit for patients with severe-to-profound hearing loss at presentation—those with the most to gain from aggressive multimodal intervention.
For clinicians, the research suggests that referral patterns for SSNHL patients might reasonably include consideration of combination therapy, particularly for those with poor prognostic factors at baseline. The study supports maintaining low thresholds for HBOT referral given its FDA-cleared status, while acknowledging that SGB addition represents a more experimental approach requiring individualized risk-benefit analysis.
Patients experiencing sudden hearing loss should understand that time is hearing. The window for effective intervention narrows rapidly after symptom onset, making prompt otolaryngologic evaluation essential. While this new research on combination therapy is intriguing, the foundational elements of SSNHL care—urgent diagnosis, corticosteroid administration, and consideration of adjunctive HBOT within the first two weeks—remain unchanged.
The stellate ganglion block findings add a promising but preliminary data point to the SSNHL literature. Prospective randomized trials would be needed to definitively establish whether the combination approach truly offers superior outcomes or whether selection effects and publication biases might explain the observed differences. Until such data emerge, the Taiwanese study provides a hypothesis-generating foundation for clinicians and patients navigating the challenging landscape of sudden hearing loss treatment.